

Vision Therapy for Convergence Insufficiency, Medical 324

Table of Content

[Description & Definitions](#)

[Criteria](#)

[Document History](#)

[Coding](#)

[Special Notes](#)

[References](#)

[Keywords](#)

[Effective Date](#) 8/1/2025

[Next Review Date](#) 5/2026

[Coverage Policy](#) Medical 324

[Version](#) 6

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details.*

Description & Definitions:

Vision Therapy are eye exercises using special lens, electronic targets with timing mechanisms, filters, prisms or other specialty tools to improve basic visual skills and abilities, as well as visual comfort, ease and efficiency.

Criteria:

Vision therapy is considered medically necessary for **all** of the following:

- Individual has indications of **1 or more** of the following:
 - Acquired convergence insufficiency
 - Congenital convergence insufficiency
- Request is from **1 or more** of the following:
 - Optometrist
 - Ophthalmologist
 - Therapist supervised by a physician.
- Request is for no more than 12 visits per calendar year

Vision therapy is **not medically necessary** for **ANY** of the following:

- More than 12 visits per calendar year
- Any other indication than acquired or congenital convergence insufficiency

Document History:

Revised Dates:

- 2025: May – Implementation date of August 1, 2025. Clarified limits. Updated to new format. Go live 7.1.2025.
- 2023: November
- 2023: May

Reviewed Dates:

- 2024: May – no changes references updated
- 2022: May
- 2021: May
- 2020: June

Coding:

Medically necessary with criteria:

Coding	Description

92065	Orthoptic and/or plooptic training, with continuing medical direction and evaluation
92066	Orthoptic training; under supervision of a physician or other qualified health care professional
92499	Unlisted ophthalmological service or procedure

Considered Not Medically Necessary:

Coding	Description
	None

U.S. Food and Drug Administration (FDA) - approved only products only.

The preceding codes are included above for informational purposes only and may not be all inclusive. Additionally, inclusion or exclusion of a treatment, procedure, or device code(s) does not constitute or imply member coverage or provider reimbursement.

Special Notes: *

- Coverage- See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.
- Application to products - Policy is applicable to Sentara Health Plan Medicare products.
- Authorization Requirements: Pre-certification by the Plan is required.
- Special Notes:
 - Medicare:
 - This medical policy expresses Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.
 - Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Federal Register. Daily Journal of the United States Government. Retrieved 4.18.2025.
<https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=Vision+Therapy+for+Convergence>

US Food and Drug Administration. Retrieved 4.21.2025.
https://www.fda.gov/search?s=convergence+special+lens&sort_bef_combine=rel_DESC

Hayes. A symplr Company. Evidence Analysis Research Brief. Aug 16, 2023. Vision Therapy for Treatment of Convergence Insufficiency in Adults. Retrieved 4.21.2025. <https://evidence.hayesinc.com/report/earb.vision5684>

Centers for Medicare and Medicaid Services. CMS.gov LCD L34512 Corneal Pachymetry. 6.09.2022. Retrieved 4.21.2025. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=34512&ver=48>

Centers for Medicare and Medicaid Services. CMS.gov NCD Computer Enhanced Perimetry (80.9). 2.15.1984. Retrieved 4.21.2025. <https://www.cms.gov/medicare-coverage-database/view/hcd.aspx?NCDId=261&NCDver=1>

Commonwealth of Virginia. Department of Medical Assistance Services. Retrieved 4.21.2025. https://vamedicaid.dmas.virginia.gov/sites/default/files/2025-02/Rehab%20Manual%20App%20D%20%28updated%202.13.25%29_Final.pdf

MCG Informed Care Strategies. 28th Edition. 2024. Retrieved 4.21.2025. <https://careweb.careguidelines.com/ed28/index.html>

National Comprehensive Cancer Network. Retrieved 4.21.2025. <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=vision%20therapy>

American Association for Pediatric Ophthalmology and Strabismus. Convergence Insufficiency. 2024. Retrieved 4.21.2025. <https://aapos.org/glossary/convergence-insufficiency#:~:text=Convergence%20Insufficiency%2092%2D%20American%20Association%20for%20Pediatrics%20Ophthalmology%20and%20Strabismus>

American Academy of Ophthalmology. What does independent research show about the effectiveness of vision therapy for children? 2012. Retrieved 4.21.2025. <https://www.aoa.org/eye-health/ask-ophthalmologist-q/vision-therapy-children>

PubMed. Aletaha, M., Daneshvar, F., Mosallaei, M., Bagheri, A., & Khalili, M. R. (2018). Comparison of Three Vision Therapy Approaches for Convergence Insufficiency. *Journal of ophthalmic & vision research*, 13(3), 307–314. Retrieved 4.21.2025. https://doi.org/10.4103/jovr.jovr_99_17

Keywords:

SHP Vision Therapy for Convergence Insufficiency, SHP Medical 324, Acquired convergence insufficiency, Congenital convergence insufficiency, Optometrist, Ophthalmologist, Commercial